Daniel Neureiter
Impact in
- Cancer Research top 2%
- MicroRNA in disease regulation
- Cancer-related molecular mechanisms research
- Oncology top 2%
- Pancreatic and Hepatic Oncology Research
Papers in
- Oncology 78
- Pancreatic and Hepatic Oncology Research 14
-
- Lymphoma Diagnosis and Treatment 18
- Co-authors
- Tobias KiesslichThomas AignerMatthias OckerE. KlieserPietro Di FazioMartin PichlerChristian MayrEckhart G. Hahn
- Journals
- International Journal of Molecular Sciences (9 papers)Cancers (8 papers)Oncotarget (6 papers)PLoS ONE (5 papers)BMC Cancer (4 papers)
- Partner nations
- AustriaGermanyUnited States
In The Last Decade
Daniel Neureiter
232 papers receiving 5.8k citations
Peers
Comparison fields: 5 of 143
- Cancer Research 906
- Oncology 1.5k
- Rheumatology 749
- Hepatology 305
- Pathology and Forensic Medicine 665
Countries citing papers authored by Daniel Neureiter
This map shows the geographic impact of Daniel Neureiter's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel Neureiter with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel Neureiter more than expected).
Fields of papers citing papers by Daniel Neureiter
This network shows the impact of papers produced by Daniel Neureiter. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel Neureiter. The network helps show where Daniel Neureiter may publish in the future.
Co-authors
The 25 scholars most cited alongside Daniel Neureiter, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 2 | |
| 2 | 2025 | 0 | |
| 3 | 2025 | 0 | |
| 4 | 2024 | 4 | |
| 5 | 2023 | 13 | |
| 6 | 2023 | 2 | |
| 7 | 2022 | 45 | |
| 8 | 2022 | 13 | |
| 9 | 2022 | 9 | |
| 10 | 2021 | 2 | |
| 11 | 2021 | 22 | |
| 12 | 2020 | 10 | |
| 13 | 2018 | 31 | |
| 14 | 2017 | 39 | |
| 15 | 2016 | 12 | |
| 16 | 2016 | 9 | |
| 17 | 2015 | 5 | |
| 18 | 2014 | 41 | |
| 19 | 2012 | 32 | |
| 20 | 2010 | 58 |
About Daniel Neureiter
Daniel Neureiter is a scholar working on Oncology, Pathology and Forensic Medicine, Hepatology, Cancer Research and Genetics, having authored 241 papers that have together received 5.9k indexed citations. Recurring topics across this work include Cholangiocarcinoma and Gallbladder Cancer Studies (30 papers), Histone Deacetylase Inhibitors Research (22 papers), Epigenetics and DNA Methylation (21 papers), Lymphoma Diagnosis and Treatment (18 papers), Gastric Cancer Management and Outcomes (17 papers), Pancreatic and Hepatic Oncology Research (14 papers), Chronic Lymphocytic Leukemia Research (14 papers) and Hedgehog Signaling Pathway Studies (12 papers). The work is most often cited by research in Cancer Research (906 citations), Oncology (1.5k citations), Rheumatology (749 citations), Hepatology (305 citations) and Pathology and Forensic Medicine (665 citations). Daniel Neureiter has collaborated with scholars based in Austria, Germany and United States. Frequent co-authors include Tobias Kiesslich, Thomas Aigner, Matthias Ocker, E. Klieser, Pietro Di Fazio, Martin Pichler, Christian Mayr, Eckhart G. Hahn, Beate Alinger and Thomas Kirchner. Their work appears in journals such as International Journal of Molecular Sciences, Cancers, Oncotarget, PLoS ONE and BMC Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.